Literature DB >> 32314092

Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk.

G Roviello1, D Villari2, R Roudi3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32314092     DOI： 10.1007/s12094-020-02352-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  1 in total

1.  Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Authors:  Giandomenico Roviello; Sebastiano Buti; Carlo Cattrini; Alessia Mennitto; Carlo Messina; Chiara Airoldi; Gianmarco Vannini; Melissa Bersanelli
Journal:  Ther Adv Urol       Date:  2021-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.